Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Trial Details

NCT ID

NCT06208657

Phase

PHASE1 / PHASE2

Sponsor

Australian & New Zealand Children's Haematology/Oncology Group

Status

RECRUITING

Cancer Type

Brain Cancer

Interventions

• Paxalisib
• Opdualag
• Irinotecan (drug)
• Temozolomide (TMZ)

Locations (sample)

• Newcastle, New South Wales, Australia|-32.92953,151.7801
• Sydney, New South Wales, Australia|-33.86785,151.20732
• Sydney, New South Wales, Australia|-33.86785,151.20732
• Brisbane, Queensland, Australia|-27.46794,153.02809
• Adelaide, South Australia, Australia|-34.92866,138.59863

Key Eligibility Criteria

• Patients must be diagnosed with a solid tumor, CNS tumor or lymphoma that has progressed despite standard therapy, or for which no effective standa…
• Age \<21 years at inclusion; patients 21 years and older may be included after approval by the Study Chair if they have a pediatric type recurrent/…
• Patients must be enrolled on a precision medicine study (i.e. PROFYLE, ZERO or equivalent as agreed with Study Chair).
• Patients enrolled in a Phase I cohort must have either evaluable or measurable disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.